Your browser doesn't support javascript.
Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo.
Nachega, Jean B; Ishoso, Daniel Katuashi; Otokoye, John Otshudiema; Hermans, Michel P; Machekano, Rhoderick Neri; Sam-Agudu, Nadia A; Bongo-Pasi Nswe, Christian; Mbala-Kingebeni, Placide; Madinga, Joule Ntwan; Mukendi, Stéphane; Kolié, Marie Claire; Nkwembe, Edith N; Mbuyi, Gisele M; Nsio, Justus M; Mukeba Tshialala, Didier; Tshiasuma Pipo, Michel; Ahuka-Mundeke, Steve; Muyembe-Tamfum, Jean-Jacques; Mofenson, Lynne; Smith, Gerald; Mills, Edward J; Mellors, John W; Zumla, Alimuddin; Mavungu Landu, Don Jethro; Kayembe, Jean-Marie.
  • Nachega JB; 1Department of Medicine, Centre for Infectious Diseases, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
  • Ishoso DK; 2Department of Epidemiology and International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
  • Otokoye JO; 3Department of Epidemiology, Infectious Diseases and Microbiology, Center for Global Health, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Hermans MP; 4Community Health Department, Kinshasa School of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.
  • Machekano RN; 5Epidemiological Surveillance Team, COVID-19 Response, Health Emergencies Program, World Health Organization, Kinshasa, Democratic Republic of the Congo.
  • Sam-Agudu NA; 6Department of Endocrinology and Nutrition, Cliniques Universitaires St-Luc, Brussels, Belgium.
  • Bongo-Pasi Nswe C; 7African Center of Biostatistics Excellence (ACBE), Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
  • Mbala-Kingebeni P; 8Department of Pediatrics, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland.
  • Madinga JN; 9International Research Center of Excellence, Institute of Human Virology Nigeria, Abuja, Nigeria.
  • Mukendi S; 10Department of Paediatrics, University of Cape Coast School of Medical Sciences, Cape Coast, Ghana.
  • Kolié MC; 11Department of Public Health, Centre Interdisciplinaire de Recherche en Ethnopharmacologie, Faculty of Medicine, Université Notre-Dame du Kasayi, Kananga, Democratic Republic of the Congo.
  • Nkwembe EN; 12Faculty of Public Health, Université Moderne de Kinkole, Kinshasa, Democratic Republic of the Congo.
  • Mbuyi GM; 13Department of Medical Microbiology and Virology, Faculty of Medicine, University of Kinshasa, National Institute of Biomedical Research (INRB), Kinshasa, Democratic Republic of the Congo.
  • Nsio JM; 5Epidemiological Surveillance Team, COVID-19 Response, Health Emergencies Program, World Health Organization, Kinshasa, Democratic Republic of the Congo.
  • Mukeba Tshialala D; 22Department of Internal Medicine, School of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of Congo.
  • Tshiasuma Pipo M; 5Epidemiological Surveillance Team, COVID-19 Response, Health Emergencies Program, World Health Organization, Kinshasa, Democratic Republic of the Congo.
  • Ahuka-Mundeke S; 13Department of Medical Microbiology and Virology, Faculty of Medicine, University of Kinshasa, National Institute of Biomedical Research (INRB), Kinshasa, Democratic Republic of the Congo.
  • Muyembe-Tamfum JJ; 14Direction Surveillance Épidémiologique (DSE), Direction Générale de Lutte contre la Maladie (DGLM), Ministère de la Santé Publique et Riposte COVID-19, Kinshasa, Democratic Republic of the Congo.
  • Mofenson L; 14Direction Surveillance Épidémiologique (DSE), Direction Générale de Lutte contre la Maladie (DGLM), Ministère de la Santé Publique et Riposte COVID-19, Kinshasa, Democratic Republic of the Congo.
  • Smith G; 15Faculty of Medicine, University of Mbuji-Mayi, Mbuji-Mayi, Democratic Republic of the Congo.
  • Mills EJ; 11Department of Public Health, Centre Interdisciplinaire de Recherche en Ethnopharmacologie, Faculty of Medicine, Université Notre-Dame du Kasayi, Kananga, Democratic Republic of the Congo.
  • Mellors JW; 13Department of Medical Microbiology and Virology, Faculty of Medicine, University of Kinshasa, National Institute of Biomedical Research (INRB), Kinshasa, Democratic Republic of the Congo.
  • Zumla A; 13Department of Medical Microbiology and Virology, Faculty of Medicine, University of Kinshasa, National Institute of Biomedical Research (INRB), Kinshasa, Democratic Republic of the Congo.
  • Mavungu Landu DJ; 16Elizabeth Glaser Pediatric AIDS Foundation, Washington, District of Columbia.
  • Kayembe JM; 17Department of Real World & Advanced Analytics, Cytel, Vancouver, Canada.
Am J Trop Med Hyg ; 103(6): 2419-2428, 2020 12.
Article in English | MEDLINE | ID: covidwho-809794
ABSTRACT
Little is known about the clinical features and outcomes of SARS-CoV-2 infection in Africa. We conducted a retrospective cohort study of patients hospitalized for COVID-19 between March 10, 2020 and July 31, 2020 at seven hospitals in Kinshasa, Democratic Republic of the Congo (DRC). Outcomes included clinical improvement within 30 days (primary) and in-hospital mortality (secondary). Of 766 confirmed COVID-19 cases, 500 (65.6%) were male, with a median (interquartile range [IQR]) age of 46 (34-58) years. One hundred ninety-one (25%) patients had severe/critical disease requiring admission in the intensive care unit (ICU). Six hundred twenty patients (80.9%) improved and were discharged within 30 days of admission. Overall in-hospital mortality was 13.2% (95% CI 10.9-15.8), and almost 50% among those in the ICU. Independent risk factors for death were age < 20 years (adjusted hazard ratio [aHR] = 6.62, 95% CI 1.85-23.64), 40-59 years (aHR = 4.45, 95% CI 1.83-10.79), and ≥ 60 years (aHR = 13.63, 95% CI 5.70-32.60) compared with those aged 20-39 years, with obesity (aHR = 2.30, 95% CI 1.24-4.27), and with chronic kidney disease (aHR = 5.33, 95% CI 1.85-15.35). In marginal structural model analysis, there was no statistically significant difference in odds of clinical improvement (adjusted odds ratio [aOR] = 1.53, 95% CI 0.88-2.67, P = 0.132) nor risk of death (aOR = 0.65, 95% CI 0.35-1.20) when comparing the use of chloroquine/azithromycin versus other treatments. In this DRC study, the high mortality among patients aged < 20 years and with severe/critical disease is of great concern, and requires further research for confirmation and targeted interventions.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hospital Mortality / Pandemics / SARS-CoV-2 / COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Country/Region as subject: Africa Language: English Journal: Am J Trop Med Hyg Year: 2020 Document Type: Article Affiliation country: Ajtmh.20-1240

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Hospital Mortality / Pandemics / SARS-CoV-2 / COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Country/Region as subject: Africa Language: English Journal: Am J Trop Med Hyg Year: 2020 Document Type: Article Affiliation country: Ajtmh.20-1240